 Packaging for the Brazilian version of NDV-HXP-S, ButanVac | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | viral vector or inactivated |
| Clinical data | |
| Trade names | ButanVac (Brazil) COVIVAC (Vietnam) HXP-GPOVac (Thailand) Patria (Mexico) |
| Other names | ADAPTCOV |
| Routes of administration | Intramuscular,[1]Intranasal |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
NDV-HXP-S (known asButanVac[2][3] orADAPTCOV[4] in Brazil,COVIVAC[5] in Vietnam,HXP-GPOVac[6] in Thailand,Patria[7] in Mexico) is aCOVID-19 vaccine candidate developed under the leadership ofPeter Palese, Adolfo García-Sastre, and Florian Krammer at theIcahn School of Medicine at Mount Sinai, in New York, United States.[8][9]
The name NDV-HXP-S comes from the termsNewcastle disease virus,HexaPro, andspike protein.[8] The stabilization of the S protein ofSARS-CoV-2 (HexaPro) was achieved byJason McLellan from theUniversity of Texas at Austin.[10]
NDV-HXP-S uses theNewcastle disease virus as itsviral vector. The platform can be live orinactivated.[9]
Unlike vaccines such as Moderna'smRNA-1273, theJanssen vaccine, and Pfizer–BioNTech'sTozinameran, which all require both specialized manufacturing facilities and also rare or expensive ingredients, NDV-HXP-S can be produced usingchicken eggs in a fashion similar to influenza vaccine production, making it especially important to and for middle- and low-income countries.[8] Those existing vaccines are based on the 2P spike, while NDV-HXP-S is further refined via the same process, resulting in a new spike called HexaPro;[10] the 2P spike contained twoprolines compared with HexaPro's six. It is also more resistant to heat and chemicals than the original 2P spike; the vaccine can be stored at 2–8 °C.[11]
Its development was coordinated by thePATH Center for Vaccine Innovation and Access, and UT Austin and ISMMS have arranged royalty-free licensing agreements with labs and corporations in 80 countries. McLellan has noted that "the share of vaccines ['low- and middle-income countries' have] received so far is terrible".[8]
As of December 2021, NDV-HXP-S is undergoing clinical trials in humans in at least four countries. In Brazil, on March 26, 2021, theButantan Institute announced it would seek to begin clinical trials. Mexico-based Avimex plans to create anintranasal spray version of the vaccine. In Thailand theGovernment Pharmaceutical Organization is conducting a trial in coordination withMahidol University.[12][13] Reflecting the freedom offered by the ease of the manufacturing process, Thai health ministerAnutin Charnvirakul referred to the vaccine as "produced by Thai people for Thai people".[8] A phase II study has been completed in Vietnam, but the phase III study has been discontinued due to shortage of unvaccinated volunteers.[14]
The Butantan trials were discontinued at phase II in late 2023 due to lack of efficacy.[15]
Earlier, Sao Paulo's Butantan biomedical institute said it will seek approval ... Butantan aims to produce 40 million doses of the Butanvac vaccine ... The vaccine was developed using a modified virus, which causes the Newcastle disease in birds ...
| Key topics |  | |
|---|---|---|
| Vietnam vaccine nominations | ||
| In popular culture | ||
